Developing Derived Induced Pluripotent Stem Cells as a Model to Understand Imprinted Disorders
Condition(s) studied
Investigational drug(s) / intervention(s)
Diagnostic Test: Molecular diagnosis carried out in the context of care
Study summary
Fetal and postnatal growth is finely regulated by genetic, epigenetic and environmental mechanisms. Parental imprinting is a regulatory mechanism that allows monoallelic expression of certain genes from a single parental allele through differential DNA methylation. Imprinted genes play a very important role in the control of fetal and postnatal growth. The pathophysiological mechanisms of these epimutations are largely unknown.
Studying the consequences of these epimutations on the molecular signature of the imprinted gene network in these patients would provide a better understanding of the epigenetic mechanisms regulating fetal growth. As these genes are weakly expressed in fibroblasts, these studies will be carried out on pluripotent stem cells or IPSCs (Induced Pluripotent Stem Cells).
Eligibility
Primary outcome measure(s)
- The objective of the study is to understand the consequences of epimutations found — 1 day
The objective of the study is to understand the consequences of epimutations found at 11p15 or 14q32 in these three syndromes (SRS, BWS and TS) on the network of genes subject to parental imprinting, in order to progress in the understanding of the mechanisms governing the epigenetic regulation of fetal growth.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hôpital Trousseau | Paris | France |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05214742 on ClinicalTrials.gov ↗ ← All trials in France